PROGRESSIVE'S EVENING STROLL DATE: 01 September, 2026

Market Snapshot:

After opening lower, a few heavyweight stocks stepped in to lift the Index. However, it failed to hold the gains, and sharp mid-session selling pushed it below the psychological 24,000 level, but the last hour surge helped the Index to trim the majority of losses to end the session at 24,055.80 with a loss of 24.60 points. Among sectors, IT was the top performer, followed by FMCG, while Capital Market and Pharma were the major laggards. In the broader market, the picture was mixed: Midcaps fell 1.39%, while Smallcaps declined just 0.23%.

HOW THE DAY TRENDED

INDICES

Index	Close	Points	%Chg.
Sensex	76944.28	(12.99)	**(0.02)**
Nifty50	24055.80	(24.60)	**(0.10)**
Nifty Midcap 100	63334.50	(890.25)	**(1.39)**
Nifty Small Cap 100	19886.25	(45.40)	**(0.23)**

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY IT	31496.70	305.25	**0.98**
NIFTY FMCG	46457.15	431.60	**0.94**
NIFTY PHARMA	26792.65	(393.80)	**(1.45)**
NIFTY CAPITAL MKT	5391.00	(94.35)	**(1.72)**

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
ITC	266.60	**4.34**	SHRIRAM FINANCE	1059.10	**(4.58)**
BHARTI AIRTEL	1877.20	**3.60**	MARUTI	12950.00	**(4.41)**
ADANI PORTS	1647.50	**3.41**	NESTLE IND	1438.20	**(3.90)**
HCL TECH	1351.40	**2.99**	MAX HEALTHCARE	1003.00	**(3.75)**

INDICES LEVELS FOR September 02, 2026

Nifty (future)	
Resistance	24250
Support	24035

Bank Nifty (future)	
Resistance	58000
Support	57250

PROGRESSIVE'S EVENING STROLL **DATE: 01 September, 2026**

KEY TAKEAWAYS OF THE DAY

- **Blackstone-backed Epsilon Bidco may sell 26% stake in EPL in Rs1,985cr block deal:**

Blackstone-backed Epsilon Bidco plans to sell its 26.4% stake in packaging firm EPL Ltd through a block deal valued at approx. Rs1,985cr. The shares are offered at Rs 235 each, marking a discount to the current market price.

- **Cipla partners SBP for breast cancer drug in India:**

Cipla partners with Hong Kong's SBP Group to bring Rolditamig Deuderuxtecan (TQB2102), a potential breast cancer drug, to India, South Africa, and other emerging markets. Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in these territories. The partnership aims to accelerate development and expand access to this promising HER2-targeted treatment.

- **ITC Infotech & Happiest Minds Technologies merge:**

Happiest Minds Technologies Ltd announced the signing of definitive agreements to combine its business with ITC Infotech India, creating a scaled AI First global technology services enterprise with USD1bn of annual revenue by FY28. As part of the transaction, ITC Infotech will acquire an aggregate minority stake of ~22.1% in Happiest Minds from the Promoter and Promoter entities across two tranches for a total consideration of Rs1,330cr (average price of Rs395/ share).

- **Sun Pharma signs US drug pricing deal, secures tariff relief for 2 years:**

The company has agreed to extend "most favoured nation" (MFN) drug pricing to US state Medicaid programmes and future innovative medicine launches in exchange for a delay in impending American tariffs, India's largest drugmaker said on September 1. Sun Pharma said the agreement recognises company's investment in the US market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years.

- **Rajesh Exports repays Rs510cr dues to Canara Bank after DRT order:**

Canara Bank recovered all dues totalling Rs510cr from Rajesh Exports. This recovery followed an order by a debt recovery tribunal. The bank initiated this action after the company blocked other recovery attempts. Rajesh Exports faced allegations of financial misrepresentation from SEBI. The bank was the largest creditor for the gold and jewellery exporter.

Source: Media Reports

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Grievance Officer:
Email: grievancecell@progressiveshares.com